Delta-Fly Pharma (4598) · FactRestated
Shift toward acquiring development candidates through major acquisitions
First written in FY2019-Q3. 1 of 2 entries say "Restated". Latest entry: FY2020-Q1.
2entries
1years
0from disclosures
How it moved
Same theme, other companies
Pharmaceutical companies’ focus on selected areas and external licensing amid soaring new drug development costsA theme 2 companies write about · 0 as a headwind · 0 as a tailwind
1 other company's latest entry also says "Restated".
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
- FY2020-Q1RestatedAnnual report
「世界の医薬品市場においては、米国アッヴィ社がアイルランド・アラガンを買収するなど、海外の大手製薬企業が事業領域の拡大や新薬開発の促進を目的として、成長戦略としてのM&Aが引き続き進められています。」
海外大手製薬企業が事業領域拡大や新薬開発促進を目的にM&Aを進める構造を再掲している。 - FY2019-Q3First statedAnnual report
「These large-scale acquisitions show that major pharmaceutical companies have already shifted their research and development strategies from building pipelines through in-house drug discovery to acquiring development candidates through corporate acquisitions.」
Describes the change in major pharmaceutical companies’ research and development strategies against the backdrop of Takeda Pharmaceutical’s acquisition of Shire and Bristol Myers Squibb’s acquisition of Celgene.